Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

NCT02183415 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: BI 1356 BS, low dose
DRUG: BI 1356 BS, medium dose
DRUG: BI 1356 BS, high dose
DRUG: Placebo

Sponsor

Boehringer Ingelheim